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Background: Wilms tumor is the most common pediatric renal malignancy and there is a clinical need for a
molecular biomarker to assess treatment response and predict relapse. The known mutated genes in this tumor
type show low mutation frequencies, whereas aberrant methylation at 11p15 is by far the most common
aberration. We therefore analyzed the epigenome, rather than the genome, to identify ubiquitous tumor-specific
biomarkers.
Results: Methylome analysis of matched normal kidney and Wilms tumor identifies 309 preliminary methylation
variable positions which we translate into three differentially methylated regions (DMRs) for use as tumor-specific
biomarkers. Using two novel algorithms we show that these three DMRs are not confounded by cell type composition.
We further show that these DMRs are not methylated in embryonic blastema but are intermediately methylated in
Wilms tumor precursor lesions. We validate the biomarker DMRs using two independent sample sets of normal
kidney and Wilms tumor and seven Wilms tumor histological subtypes, achieving 100% and 98% correct
classification, respectively. As proof-of-principle for clinical utility, we successfully use biomarker DMR-2 in a pilot
analysis of cell-free circulating DNA to monitor tumor response during treatment in ten patients.
Conclusions: These findings define the most common methylated regions in Wilms tumor known to date which are
not associated with their embryonic origin or precursor stage. We show that this tumor-specific methylated DNA is
released into the blood circulation where it can be detected non-invasively showing potential for clinical utility.Background
Wilms tumor (WT) is the most common pediatric renal
cancer with a prevalence of one in 10,000 children [1].
In Europe, most patients receive four weeks of pre-
operative chemotherapy prior to complete or partial
nephrectomy, followed by tumor stage and histology-
dependent post-operative treatment [2]. Although over-
all survival rates are good, there is a clinical need for a
biomarker to evaluate patient response to chemotherapy
and improve prediction of relapse.
Circulating cell-free DNA (cfDNA) isolated from blood
has been used to assess tumor burden in other cancers
[3-6]. In WT, the few genes that are recurrently mutated
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unless otherwise stated.(15%) [8] and WT1 (12%) [8] - and do not account for the
majority of WTs. However, epimutation affecting the IGF2/
H19 locus at 11p15.5 is much more common (69%) [8].
Additional genes and regions known to be affected by
methylation in WT include GLIPR1 [9], imprinted genes
NNAT [10] and the WT1-antisense region [11], various
satellite regions [12,13], HACE1 [14], RASSF1A [15], P16
and the protocadherin cluster at 5q31 [16]. Consequently,
we concluded that interrogation of the methylome rather
than the genome may be more likely to reveal ubiquitous
tumor-specific biomarkers. Therefore, we performed genome-
wide methylome analysis of matched WT and surroun-
ding normal kidney (NK) to identify WT-specific sites
of methylation which we then assessed in cfDNA for
use as WT biomarkers.Results
To identify tumor-specific methylation variable positions
(MVPs), as previously defined [17], we derived methylationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CpG sites at single base-pair resolution using the Illumina
Infinium HumanMethylation450 platform and performed
linear modeling to compare 22 matched pairs of NK
and WT (full clinical details in Additional file 1). We iden-
tified 309 MVPs of genome-wide significance (P < 5 × 10-8;
Figure 1). Due to the matched study design there was no
need to adjust for age, race or gender and we can exclude
the possibility of MVPs being confounded by genetic poly-
morphism(s). We then applied the novel pipeline Lasso,
recently developed for analysis of Illumina 450 k data,
which considers the local CpG density to group MVPs
into functionally more relevant differentially methylated
regions (DMRs) [18]. Using this method, we identified
three DMRs which were hypermethylated in WT with
respect to NK (Table 1).
To assess possible confounding due to differential cell
type composition, we carried out two analyses. First, we
conducted histological analysis confirming our samples to
be composed of the expected major cell types, consisting
of 95% epithelia and 5% stroma in NK while WT showed
varying proportions of immature stroma, epithelia andFigure 1 Identification of differentially methylated loci with genome-
(462,537) generated by linear modeling of normal kidney (NK) against Wilm
above the red line. DMR-1 and DMR-2 on chromosome 6 and DMR-3 on cblastema (Figure S1 in Additional file 2). Second, we used
a recently published algorithm, RefFreeEWAS [19], which
corrects P-values based on estimated cell type contribu-
tions. Performing linear modeling using this algorithm,
we identified 7,272 CpGs with genome-wide significance
(P < 5 × 10-8) of which 937 had Δβ > 0.3 and were there-
fore considered cell composition-corrected MVPs. Of
these, 766 were hyperMVPs and 171 were hypoMVPs in
WT with respect to NK (Additional file 3). For hyperMVPs
in particular, we saw a striking positive enrichment for
location within CpG islands (+18% compared to back-
ground). There were 483 CpG islands targeted by aberrant
methylation in total (Additional file 4) with a varying num-
ber of corrected MVPs per island. The greatest enrichment
of MVPs occurred in two CpG islands on chromosome 6
(CpG:56 and CpG:42) with 13 and 11 MVPs, respectively,
which overlapped with DMR-1 and -2. Using a threshold
of ≥3 MVPs per DMR, we then mapped the cell type-
corrected MVPs onto the DMRs identified with Lasso,
confirming that all three DMRs were not confounded by
cell composition effects. We therefore continued our
analysis focusing on DMR-1 to -3.wide significance. Manhattan plot showing -log10 P-values for all CpGs
s tumor (WT). CpGs with genome-wide significance (n = 309) appear
hromosome 11 are shown in green.
Table 1 Differentially methylated regions hypermethylated in Wilms tumor compared to normal kidney
DMR Location First CpG Last CpG Size (bp) Number of CpGs DMR P-value CpG island Nearest gene
1 6p22.1 28956226 28956426 200 8 1.58E-10 CpG:42 ZNF311
2 6p21.32 32116905 32116963 58 3 4.67E-09 CpG:56 PRRT1
3 11q13.5 76858947 76859056 109 3 2.48E-09 CpG:38 MYO7A
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(βmean), we found that WT had significantly greater
levels of methylation with respect to NK for the disco-
very dataset as well as an independent dataset of 12 pairs
(P = 3.85 × 10-17 and P = 9.26 × 10-10, respectively, two-
tailed t-test; Figure 2a,b). Furthermore, βmean was consis-
tently high across an independent cohort of fresh frozen
WT (n = 86; Table S4 in Additional file 2) encompassing
the seven post-chemotherapy WT histological subtypes
classified into two risk groups, as defined by the Inter-
national Society of Paediatric Oncology [20] (SIOP;
Figure 2c). Within this cohort, a significant difference was
seen between WT risk groups (P = 0.0024, 2-tailed T-test)
with more elevated methylation levels observed in high
risk WT (average βmean = 0.87 vs. 0.78). Based on methy-
lation levels in the discovery dataset, a support vector
machine (using R package e1071) correctly classified 100%
and 98% samples within each replication set respectively
indicating the discriminative potential of these DMRs as
biomarkers. Clinical details for both of these cohorts can
be found in Additional file 1: Table S1.
DMR-1 and -2 are located within the extended major
histocompatibility complex (MHC) region [21]. Although
the MHC is highly polymorphic [22], our matched study
design controlled for any genetic heterogeneity, ensuringFigure 2 Methylation levels for DMR-1 to -3 significantly distinguish n
Aggregated methylation levels across DMR-1 to -3 significantly separate no
P = 3.85 × 10-17) (a) and in the replication set (n = 12 pairs, P = 1.47 × 10-9) (
including high risk (dark green, n = 25) and intermediate risk histological su
methylation levels than intermediate risk WT (P = 0.0024). (d) Whole bloodthat the observed signal was not confounded by copy
number or other DNA sequence variation. We validated
methylation levels for these DMRs using bisulfite-
sequencing (Figure S3 and Table S5 in Additional file 2)
and confirmed the absence of C > T mutation. MHC clus-
ter hypermethylation and reciprocal loss of gene expres-
sion is common across cancers as a mechanism to evade
immunosurveillance and increase oncogenic potential
[23-26]. To further explore the association between DMR
methylation and tumorigenesis, we extracted DNA from
three specimens of human embryonic kidney (EK; gesta-
tional age = 22, 22 and 23 weeks) and separately micro-
dissected embryonic blastema (EB; n = 3; the predicted
WT cell of origin). Bisulfite sequencing of DMR-1 and -2
showed average β-values of 0.007 for EK and 0.12 for
EB. Furthermore, analysis of methylation levels in 20
cases with matched WT precursor lesions termed nephro-
genic rests (NRs) showed intermediate methylation levels
(Figure S2 in Additional file 2). Put together, these data
suggest that sequential increase in methylation levels is
associated with transformation of embryonic precursor
cells towards a malignant phenotype.
As all DMRs were methylated in WT in comparison
to NK, we predicted that levels of methylated DNA in
the circulation may increase with tumor burden. Whenormal kidney from Wilms tumour and whole blood. (a,b)
rmal kidney (blue) and Wilms tumor (pink) in the test set (n = 22 pairs,
b). (c) Methylation levels were high in an independent dataset of WT
btypes (light green, n = 61). High risk WT showed significantly higher
(n = 411) shows low methylation levels (red).
Figure 3 Levels of methylation in serum cfDNA during WT
treatment. Levels of %Mmean (for 14 CpGs within DMR-2) show
significant differences between controls and pre-op samples
(P= 0.010), controls and post-op samples (P= 0.017), pre-chemotherapy
and pre-op (P= 0.028) and pre-chemotherapy and post-op (P= 0.047;
all by two-tailed t-test). Data show increasing levels of methylated
cfDNA associated with WT necrosis. Level of significance is shown
asterisks (*P < 0.05; **P< 0.01) with horizontal lines indicating the
respective comparison.
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proportions of leukocyte subpopulations can alter the
overall methylation signal, giving false yield [27]. There-
fore, to assess the potential influence that blood popula-
tions may have on our dataset, we examined publically
available methylation signatures that define normal per-
ipheral blood subgroups [28] as well as methylation
levels of normal whole blood (extracted using Marmal-
aid [29]; n = 411). We found that DMR-1 to -3 did not
overlap with any blood-related methylation signature,
and that normal blood methylation levels for DMR-1 to
-3 were extremely low (average βm = 0.12; Figure 2d).
Therefore, we concluded that the WT-specific hyper-
methylated DMRs were not detected as a result of shifts
in leukocyte populations in chemotherapy-treated tissue.
Hence, we explored the potential of DMR-1 to -3 as
tumor-specific blood biomarkers, as they should be
detectable above a low background and should not be
confounded by shifts in leukocyte populations in the
circulation.
To test the potential efficacy of these biomarkers, we
performed bisulfite-sequencing of DMR-2 on cfDNA iso-
lated from serum samples taken from 10 children with
WT at diagnosis, during pre-operative chemotherapy and
following nephrectomy as well as four cancer-free age-
matched control serum samples (Table S6 in Additional
file 2). The entire sequenced region (chr6:32,116,940-
32,117,259) spanned 319 bp and included 44 CpGs, many
of which showed either no variation or extreme variation
in methylation between samples. Therefore, to identify
CpGs that showed consistent methylation at one time-
point and differential methylation between time-points,
we grouped samples within each time-point and per-
formed an ANOVA test. From this, we selected a subset
of CpGs (n = 14) that showed differential methylation
between at least one pair of groups, irrespective of direc-
tionality of methylation changes, avoiding those with very
low variance. Aggregating the percentage of methylated
cfDNA across these 14 CpGs (%Mmean) showed that con-
trol samples had the lowest levels of methylated cfDNA
(13.4) and that children with WT had relatively higher
levels taken at diagnosis before treatment starts (14.5).
There was then a substantial and significant increase in
the level of methylated cfDNA taken after the pre-
operative chemotherapy phase (19.9) that persisted into
the immediate post-operative period (19.2) (Figure 3). This
proof-of-principle experiment establishes DMR-2 as a
potential blood-based biomarker for WT.
Discussion
This study has identified three DMRs with genome-wide sig-
nificance in WT that are present in nearly all WT (118 out
of a total of 120 WTs examined) and are not mediated by
cell type composition. In comparison to previous mutationalstudies, our epigenetic biomarker is far more ubiquitous and
even supersedes 11p15 epimutation (found in approximately
70% of WT cases) as the most common biomarker in WT.
Therefore, our results suggest that analysis of an epigenetic
mark in cfDNA could be more successful than analysis of
tumor-specific somatic mutations, which are much less
common. Furthermore, our study revealed a significant
difference in methylation levels between intermediate and
high risk WT which could be of diagnostic use and suggest
a use for novel therapeutic approaches to high risk WT.
Although the NK samples do not contain blastema but
WT samples do, our correction for cell type composition
compensates for these effects, allowing for identification
of three true DMRs that are not mediated by cell
mixture effects. Methylation analysis of DMR-1 and -2
in EK and EB showed that these regions are not methyl-
ated in the presumed WT cell of origin. Analysis of NRs
showed that the precursor lesion had intermediate levels
of methylation at the same regions which were then
further methylated in the associated tumors (Figure S2
in Additional file 2). We therefore concluded that
increased methylation at these loci is associated with
tumorigenic transformation and is not simply a mani-
festation of the embryonic origin of these tumors. Fur-
thermore, as 84/86 WTs were correctly classified by
methylation status in our independent cohort, which
included tumors stratified into all seven histological
subtypes, and consistent high levels of methylation were
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their variable cellular composition (Figure S1 in Additional
file 2), we can conclude that all cells constituting the
tumor contributed to the observed gain of methylation.
Our data suggest that WT release methylated DMR-2
cfDNA (M-cfDNA) following exposure to chemotherapy.
Supporting this, a higher proportion of M-cfDNA (%Mmean
of 23.6 compared to 17.3) was observed in serum sampled
after pre-operative chemotherapy in patients with the
regressive subtype of WT, defined by more than two-thirds
necrosis in the nephrectomy specimen, compared with
patients with other WT subtypes that show less than two-
thirds necrosis in response to chemotherapy [20]. In this
small ‘proof-of-principle’ case series, we noted that post-
operative M-cfDNA levels remained high in the immediate
post-operative period, sampled at day 4 up to 24 days
post-surgery. This short-term persistence may be due to
the fact that serum cfDNA can retain interaction with
nucleosome proteins which protects the DNA from
degradation, rendering it relatively stable [30]. This may
also explain our ability to sequence such a long fragment
(319 bp). A full post-surgery time course is required to
assess this rate of degradation. Interestingly, one patient
showed post-operative M-cfDNA levels 1.3-fold greater
than the group mean; a 22% increase post-surgery. We
hypothesize that this post-surgery increase in M-cfDNA
may be due to residual tumor within the patient and, in-
deed, three months later, bone metastasis was detected.
Conclusions
We have defined the first epigenetic biomarker for the
analysis of circulating cfDNA in WT patients. We show
that this may be useful to improve the accuracy of deter-
mining tumor response during pre-operative chemo-
therapy and predicting the histological risk group. This
could allow appropriate modification of treatment prior
to planned nephrectomy, particularly important for
surgical planning in bilateral WT, where maximizing
tumor response to allow partial nephrectomy is the goal.
Due to the low relapse rate in WT, a much larger,
prospectively collected sample series of patients is
required to demonstrate clinical utility as a prognostic
biomarker for relapse-free survival. Based on these
‘proof-of-principle’ findings, a European multi-center
clinical trial with appropriate sampling is planned to
rigorously test whether analysis of this epigenetic biomarker
would improve the accuracy of prediction of relapse in
all cases.
Materials and methods
Sample selection
Use of patient samples in this study was conducted with
appropriate parental written consent and ethical approval
granted by the NHS London Bridge Research EthicsCommittee (reference 12/LO/0101) with experiments
performed in compliance with the Helsinki Declaration.
Patients were enrolled in the UK either into the SIOP
Wilms Tumour 2001 Clinical Trial and Study or the
Improving Patient Outcomes for Renal Tumours of
Childhood (IMPORT) study, with appropriate parental
written consent. Blood serum samples from age-matched
controls without cancer were taken from Great Ormond
Street Hospital Department of Chemical Pathology with
parental written consent. Marmal-aid v1.2.1 [31] was used to
extract publically available methylation data annotated as
disease = ‘Healthy’ and tissue = blood (n = 411). EK was
obtained from fetal post-mortem examinations carried out
at the Fetal Pathology Unit, University Hospital of Wales
with written parental consent.
DNA extraction
As NR can only be identified by pathological review of
hematoxylin and eosin (H&E)-stained formalin-fixed
paraffin embedded (FFPE) sections, 3 μm H&E sections
from post-nephrectomy FFPE blocks were studied by
two independent pediatric pathologists who marked out
regions of NK, NR and WT. A total of 22 matched trios
(NK, NR and WT) and 12 matched pairs of NK and WT
(90 samples) were microdissected by cutting multiple
5 μm sections and removing the desired region with a
scalpel. EB was also microdissected from 5 μm FFPE
sections following a master H&E section as a guide.
Tissue was taken from the whole section without micro-
dissection to extract DNA from whole EK. Fresh frozen
(FF) tissue (n = 86 samples) was taken from 83 patient
nephrectomies that were classified according to centra-
lized SIOP pathology review, including stromal (n = 15),
epithelial (n = 10), blastemal (n = 11), mixed (n = 23), dif-
fuse anaplastic (n = 14), focal anaplasia (n = 2) or regres-
sive (n = 11) type. DNA was extracted from FFPE and FF
tissue using the DNeasy Blood and Tissue Kit (QIAGEN,
Hilden, Germany) but with the manufacturer’s instruc-
tions modified for FFPE DNA: samples were heated to
90°C for 1 hour post-incubation at 56°C and incubated
at 70°C for 10 minutes with buffer AL. For cfDNA analysis,
DNA was extracted from pre-chemotherapy (n = 5), pre-
operative (n = 8) or post-operative (n = 8) patient serum
and age-matched cancer-free control serum (n = 7) using
the QIAamp Circulating Nucleic Acid kit (QIAGEN).
Genome-wide methylation analysis
DNA extracted from FFPE specimens (n = 90) was first
treated using the REPLIg FFPE kit (QIAGEN) [32]. Both
FF (n = 86) and treated FFPE DNA was then bisulfite-
converted using the EZ DNA Methylation Kit (Zymo
Research Corp, Orange, CA, USA) and interrogated using
the Illumina 450 k platform. Two FFPE NR samples failed
stringent quality control metrics and were excluded. For
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in R [33] or Bioconductor [34] were used as indicated.
Raw data were filtered to exclude samples with detection
P-value <0.01 and normalized using subset within quantile
normalisation (SWAN) using the Bioconductor R package
ChAMP version 2.14 [18,35]. For initial MVP detection
the normalized data matrix for 22 pairs (NK and WT) was
included. Bayesian framework linear modeling using the
Bioconductor R package Limma [36] version 3.20.4 [37]
was performed to find sites of differential methylation that
varied between NK and WT pairs and that were common
across patients, which avoids false positives from patient-
specific SNPs or age effects. To this model, the TREAT
function was applied to adjust P-values based on the Δβ-
value (>0.1) [38], which were further adjusted to correct
for multiple testing [39]. The DMR-lasso algorithm in
the ChAMP package was then used to find DMRs [18]
with settings adjusted to include only CpGs that reach
genome-wide significance (P < 5 × 10-8). To the same
model, we applied the RefFreeEWAS algorithm [19],
which uses single value decomposition to estimate the
number of cell types contributing to overall histology. The
algorithm then deconvoluted the β-values based on the
estimated number of cell types (d = 3) and a design matrix
specifying patient pairs and sample histology, and gene-
rated bootstrap-derived CpG-specific P-values and cova-
riates that correspond to a ‘true’ methylation signal with
no cell mixture effects.
After confirming our three DMRs were not due to cell
composition effects, the DMR values were compared
with levels in a replication dataset of 12 pairs, the inde-
pendent set of 86 FF WT and the matched NRs for 20
cases. Sample classification (by support vector machine)
was performed using the 22 pairs as a training set and
12 pairs and 86 WT as separate test sets using R CRAN
package e1071 [40].
Assessment of DMR methylation by bisulfite-sequencing
Of the three DMRs, we chose to validate methylation
levels for DMR-1 and -2 by sequencing both bisulfite-
converted and normal DNA from nine NK and WT pairs.
We performed the same experiment to assess methylation
levels in EK and EB. Bisulfite reads for DMR-1 showed
poor coverage with only 6/18 validation samples giving
sufficient reads (Table S5 in Additional file 2). We there-
fore chose to focus on DMR-2 for detection in cfDNA
from 28 serum samples. For cfDNA analysis, 5/21 patient
(3 pre-op, 2 post-op) and 3/7 control samples failed to
generate sufficient sequence reads for analysis.
Primers were designed (Table S7 in Additional file 2)
using Primer 3 [41] and MethPrimer [42] and optimized
using commercial DNA. DNA for bisulfite-sequencing
was converted using the EZ DNA methylation kit (Zymo
Research). Library preparation PCRs were performedusing NEBNext (New England Biolabs, Beverly, MA,
USA) and KAPA HiFi Uracil + (KAPA Biosystems Inc,
Wilmington, MA, USA). Products were cleaned using
magnetic beads (Beckman Coulter Inc, Brea, CA, USA)
and quantified using Picogreen reagents. Sample-specific
tags were added prior to sequencing using the Illumina
Mi-Seq. Raw bisulfite-converted paired-end reads were
mapped to human genome build hg19 with Bismark
v0.9.0 [43] using Bowtie 2 [44] as the aligner. Methylated
and unmethylated base counts were generated with the
bismark_methylation_extractor utility and exported as
BedGraph files for further analysis and display in IGV
[45]. Aligned BAM files were sorted and indexed with
SAMtools [46] for assessment of the regions of interest
in IGV. The number of C reads divided by total reads
per CpG site was then calculated to discern the percent-
age level of methylation per sample.
To generate allele counts for the full sequence of
DMR-2, we used the ANGSD package [47]. ANOVA
was performed in R using Bioconductor package Limma
to make all possible contrasts between groups. CpGs
were selected for further analysis if the Limma Toptable
moderated F score >1, indicating that any of the
contrasts between groups were non-zero and if group
variance for that CpG was >1.
Data access
The 450 k methylation data described in this study are
available from the Gene Expression Omnibus [48] with
accession ID GSE59157.
Additional files
Additional file 1: Table S1. Clinical information for the discovery
cohort (n = 22), validation set 1 (n = 12) and validation set 2 (n = 86).
Additional file 2: Figure S1. quantification of cell proportions in each
micro-dissected Wilms tumor (WT) section used for DNA extraction in the
discovery cohort. Figure S2: WT precursor lesions show intermediate
methylation at significant differentially methylated regions (DMRs).
Figure S3: comparison of methylation values assessed by 450 k array and
bisulfite sequencing. Table S4: fresh frozen WT (n = 86) classified by
overall tumor histology with average methylation β-values across all
significant DMR CpGs. Table S5: validation of 450 k methylation signal by
bisulfite-sequencing. Table S6: clinical information on patients from
which cfDNA was isolated. Table S7: list of primers used.
Additional file 3: Table S2. A list of all cell-corrected methylation variable
positions (n = 937).
Additional file 4: Table S3. A list of the CpG islands (n = 483) that
contained significantly hypermethylated or hypomethylated cell-corrected
MVPs, with the respective number of CpGs per island.
Abbreviations
bp: base pair; cfDNA: circulating cell-free DNA; DMR: differentially methylated
region; EB: embryonic blastema; EK: embryonic kidney; FF: fresh frozen;
FFPE: formalin fixed paraffin embedded; H&E: hematoxylin and eosin;
IMPORT: Improving Population Outcomes for Children with Renal Tumors;
M-cfDNA: methylated cell-free DNA; MHC: major histocompatibility complex;
MVP: methylation variable position; NK: normal kidney; NR: nephrogenic rest;
Charlton et al. Genome Biology 2014, 15:434 Page 7 of 8
http://genomebiology.com/2014/15/8/434PCR: polymerase chain reaction; SIOP: International Society of Paediatric
Oncology; WT: Wilms tumor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JC performed DNA extraction from FFPE tissue and serum samples and
carried out library preparation for bisulfite sequencing. NJS, SP and WM
marked out regions of NK, NR and WT for DNA extraction from FFPE tissue.
GV and NJS are the National Reference Panel pathologists for the UK cases
in the SIOP WT 2001 and IMPORT trials. GV also supplied embryonic fetal
kidney specimens. JC performed bioinformatics analyses with help from
RDW. LMB provided analysis tools. MA-G contributed data from a cohort of
86 fresh frozen tumors. MW co-ordinates the clinical study (IMPORT) that
collects serial blood samples of patients with WT during therapy. SB and KP-J
conceived the study. JC wrote the manuscript with input from all authors.
All authors approved the final version.
Acknowledgements
JC was funded by the UCL Grand Challenges Scheme and the Olivia Hodson
fund. The Pritchard-Jones laboratory was funded by Cancer Research UK
(C1188/A4614), Great Ormond Street Hospital (GOSH) Children’s Charity and
Children with Cancer (11MH16) and EU-FP7 project ENCCA (261474). NJS and
KPJ are part supported by the NIHR GOSH UCL Biomedical Research Centre.
The Beck laboratory was funded by the Wellcome Trust (99148), the UCL
Biomedical Research Centre (BRC84/CN/SB/5984), a Royal Society Wolfson
Research Merit Award (WM100023), IMI-JU OncoTrack (115234) and EU-FP7
projects IDEAL (259679), EPIGENESYS (257082) and BLUEPRINT (282510).
The authors would like to thank all the investigators at the contributing
Children’s Cancer and Leukaemia Group (CCLG) treatment centers and the
CCLG tissue bank, which is funded by Cancer Research UK, for provision of
samples. We thank Tasnim Chagtai and Becky West for processing of frozen
tumor samples, Tessa Kasia, Lucy Bailey and Darren Edwards of the Great
Ormond Street Hospital Translational Cancer Research Team for collection
of tissue samples, the Department of Chemical Pathology at Great Ormond
Street Hospital including Helen Aitkenhead, Principal Clinical Scientist,
and Daley Aofolaju, Chief Biomedical Scientist for providing control serum
samples. We thank Kerra Pearce and Tony Brooks from UCL Genomics for their
help with processing the Illumina 450 k arrays and the Illumina sequencing.
Author details
1UCL Institute of Child Health, University College London, 30 Guilford Street,
London WC1N 1EH, UK. 2The Institute of Cancer Research, 15 Cotswold Road,
Sutton, Surrey SM2 5NG, UK. 3Department of Pathology, Cardiff University
School of Medicine, Heath Park, Cardiff CF14 4XN, UK. 4UCL Cancer Institute,
University College London, 72 Huntley Street, London WC1E 6BT, UK.
Received: 8 July 2014 Accepted: 8 August 2014
Published: 19 August 2014
References
1. Breslow N, Olshan A, Beckwith JB, Green DM: Epidemiology of Wilms
tumor. Med Pediatr Oncol 1993, 21:172.
2. Lemerle J, Voute PA, Tournade MF, Rodary C, Delemarre JF, Sarrazin D,
Burgers JM, Sandstedt B, Mildenberger H, Carli M: Effectiveness of
preoperative chemotherapy in Wilms’ tumor: results of an International
Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol 1983,
1:604.
3. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, Ratschiller D,
Weder W, Joerger M, Betticher DC, Stahel RA, Ziegler A: Circulating
deoxyribonucleic acid as prognostic marker in non–small-cell lung
cancer patients undergoing chemotherapy. J Clin Oncol 2004, 22:4157.
4. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K,
Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA Jr:
Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14:985.
5. Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de las Peñas R,
Sanchez JM, Moran T, Camps C, Massuti B, Sanchez JJ, Salazar F, Catot S:
14-3-3σ Methylation in pretreatment serum circulating DNA of
cisplatin-plus-gemcitabine-treated advanced Non–small-cell lung cancerpatients predicts survival: the Spanish Lung Cancer Group. J Clin Oncol
2005, 23:9105.
6. Mori T, O’Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, Kuo C,
Takeshima T-L, Milford R, Wang H-J, Vu VD, Nguyen SL, Hoon DSB: Predictive
utility of circulating methylated DNA in serum of melanoma patients
receiving biochemotherapy. J Clin Oncol 2005, 23:9351.
7. Ruteshouser EC, Robinson SM, Huff V: Wilms tumor genetics: mutations in
WT1, WTX, and CTNNB1 account for only about one-third of tumors.
Genes Chromosomes Cancer 2008, 47:461.
8. Scott RH, Murray A, Baskcomb L, Turnbull C, Loveday C, Al-Saadi R, Williams
R, Breatnach F, Gerrard M, Hale J, Kohler J, Lapunzina P, Levitt GA, Picton S,
Pizer B, Ronghe MD, Traunecker H, Williams D, Kelsey A, Vujanic GM,
Sebire NJ, Grundy P, Stiller CA, Pritchard-Jones K, Douglas J, Rahman N:
Stratification of Wilms tumor by genetic and epigenetic analysis.
Oncotarget 2012, 3:327.
9. Chilukamarri L, Hancock AL, Malik S, Zabkiewicz J, Baker JA, Greenhough A,
Dallosso AR, Huang TH, Royer-Pokora B, Brown KW, Malik K: Hypomethylation
and aberrant expression of the glioma pathogenesis-related 1 gene in
Wilms tumors. Neoplasia 2007, 9:970.
10. Hubertus J, Zitzmann F, Trippel F, Muller-Hocker J, Stehr M, von Schweinitz
D, Kappler R: Selective methylation of CpGs at regulatory binding sites
controls NNAT expression in Wilms tumors. PLoS One 2013, 8:e67605.
11. Malik K, Salpekar A, Hancock A, Moorwood K, Jackson S, Charles A,
Brown KW: Identification of differential methylation of the WT1 antisense
regulatory region and relaxation of imprinting in Wilms’ tumor.
Cancer Res 2000, 60:2356.
12. Ehrlich M, Hopkins NE, Jiang G, Dome JS, Yu MC, Woods CB, Tomlinson GE,
Chintagumpala M, Champagne M, Dillerg L, Parham DM, Sawyer J:
Satellite DNA hypomethylation in karyotyped Wilms tumors.
Cancer Genet Cytogenet 2003, 141:97.
13. Ludgate JL, Le Mee G, Fukuzawa R, Rodger EJ, Weeks RJ, Reeve AE,
Morison IM: Global demethylation in loss of imprinting subtype
of Wilms tumor. Genes Chromosomes Cancer 2012, 52:174–184.
14. Zhang L, Anglesio MS, O’Sullivan M, Zhang F, Yang G, Sarao R, Mai PN,
Cronin S, Hara H, Melnyk N, Li L, Wada T, Liu PP, Farrar J, Arceci RJ, Sorensen
PH, Penninger JM: The E3 ligase HACE1 is a critical chromosome 6q21
tumor suppressor involved in multiple cancers. Nat Med 2007, 13:1060.
15. Wagner KJ, Cooper WN, Grundy RG, Caldwell G, Jones C, Wadey RB, Morton
D, Schofield PN, Reik W, Latif F, Maher ER: Frequent RASSF1A tumour
suppressor gene promoter methylation in Wilms’ tumour and colorectal
cancer. Oncogene 2002, 21:7277.
16. Dallosso AR, Hancock AL, Szemes M, Moorwood K, Chilukamarri L, Tsai HH,
Sarkar A, Barasch J, Vuononvirta R, Jones C, Pritchard-Jones K, Royer-Pokora
B, Lee SB, Owen C, Malik S, Feng Y, Frank M, Ward A, Brown KW, Malik K:
Frequent long-range epigenetic silencing of protocadherin gene clusters
on chromosome 5q31 in Wilms’ tumor. PLoS Genet 2009, 5:e1000745.
17. Rakyan VK, Beyan H, Down TA, Hawa MI, Maslau S, Aden D, Daunay A,
Busato F, Mein CA, Manfras B, Dias KR, Bell CG, Tost J, Boehm BO, Beck S,
Leslie RD: Identification of type 1 diabetes-associated DNA methylation
variable positions that precede disease diagnosis. PLoS Genet 2011,
7:e1002300.
18. Morris T, Butcher L, Feber A, Teschendorff A, Chakravarthy A, Wojdacz T,
Beck S: 450 k Chip Analysis Methylation Pipeline (ChAMP). Bioinformatics
2013, 30:428–430.
19. Houseman EA, Molitor J, Marsit CJ: Reference-free cell mixture adjustments
in analysis of DNA methylation data. Bioinformatics 2014, 30:1431.
20. Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I, de Kraker J:
Revised International Society of Paediatric Oncology (SIOP) working
classification of renal tumors of childhood. Med Pediatr Oncol 2002, 38:79.
21. Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ,
Povey S, Talbot CC Jr, Wright MW, Wain HM, Trowsdale J, Ziegler A, Beck S:
Gene map of the extended human MHC. Nat Rev Genet 2004, 5:889.
22. de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J, Ke X,
Monsuur AJ, Whittaker P, Delgado M, Morrison J, Richardson A, Walsh EC,
Gao X, Galver L, Hart J, Hafler DA, Pericak-Vance M, Todd JA, Daly MJ,
Trowsdale J, Wijmenga C, Vyse TJ, Beck S, Murray SS, Carrington M,
Gregory S, Deloukas P, Rioux JD: A high-resolution HLA and SNP
haplotype map for disease association studies in the extended
human MHC. Nat Genet 2006, 38:1166.
23. Garrido C, Paco L, Romero I, Berruguilla E, Stefansky J, Collado A, Algarra I,
Garrido F, Garcia-Lora AM: MHC class I molecules act as tumor suppressor
Charlton et al. Genome Biology 2014, 15:434 Page 8 of 8
http://genomebiology.com/2014/15/8/434genes regulating the cell cycle gene expression, invasion, and intrinsic
tumorigenicity of melanoma cells. Carcinogenesis 2012, 33:687–693.
24. Doyle A, Martin WJ, Funa K, Gazdar A, Carney D, Martin SE, Linnoila I,
Cuttitta F, Mulshine J, Bunn P, Minna J: Markedly decreased expression
of class I histocompatibility antigens, protein, and mRNA in human
small-cell lung cancer. J Exp Med 1985, 161:1135.
25. Jäger E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jäger D,
Oesch F, Knuth A: Immunoselection in vivo: Independent loss of MHC
class I and melanocyte differentiation antigen expression in metastatic
melanoma. Int J Cancer 1997, 71:142.
26. Degenhardt Y, Huang J, Greshock J, Horiates G, Nathanson K, Yang X,
Herlyn M, Weber B: Distinct MHC gene expression patterns during
progression of melanoma. Gene Chromosome Cancer 2010, 49:144.
27. Adalsteinsson BT, Gudnason H, Aspelund T, Harris TB, Launer LJ, Eiriksdottir
G, Smith AV, Gudnason V: Heterogeneity in white blood cells Has
potential to confound DNA methylation measurements. PLoS One 2012,
7:e46705.
28. Koestler DC, Marsit CJ, Christensen BC, Accomando W, Langevin SM,
Houseman EA, Nelson HH, Karagas MR, Wiencke JK, Kelsey KT:
Peripheral blood immune cell methylation profiles are associated with
nonhematopoietic cancers. Cancer Epidemiol Biomarkers Prev 2012, 21:1293.
29. Lowe R, Rakyan VK: Marmal-aid–a database for Infinium
HumanMethylation450. BMC Bioinformatics 2013, 14:359.
30. Rumore PM, Steinman CR: Endogenous circulating DNA in systemic lupus
erythematosus. Occurrence as multimeric complexes bound to histone.
J Clin Investig 1990, 86:69.
31. MARMAL-AID. [http://marmal-aid.org/].
32. Thirlwell C, Eymard M, Feber A, Teschendorff A, Pearce K, Lechner M,
Widschwendter M, Beck S: Genome-wide DNA methylation analysis of
archival formalin-fixed paraffin-embedded tissue using the Illumina
Infinium HumanMethylation27 BeadChip. Methods 2010, 52:248.
33. R: A language and environment for statistical computing. [http://www.
r-project.org/].
34. Bioconductor. [http://www.bioconductor.org/].
35. Bioconductor ChAMP package. [http://www.bioconductor.org/packages/
release/bioc/html/ChAMP.html].
36. Smyth GK: Limma. In Bioinformatics and Computational Biology Solutions
Using R and Bioconductor. Volume 23. Edited by Gentleman R, Carey V,
Huber W, Irizarry R, Dudoit S. New York: Springer; 2005:397–420.
37. Bioconductor Limma package. [http://www.bioconductor.org/packages/
release/bioc/html/limma.html].
38. McCarthy DJ, Smyth GK: Testing significance relative to a fold-change
threshold is a TREAT. Bioinformatics 2009, 25:765.
39. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J Roy Stat Soc B
(Methodological) 1995, 57:589.
40. e1071 package. [http://cran.r-project.org/web/packages/e1071/index.html].
41. Koressaar T, Remm M: Enhancements and modifications of primer design
program Primer3. Bioinformatics 2007, 23:1289–1291.
42. Li LC, Dahiya R: MethPrimer: designing primers for methylation PCRs.
Bioinformatics 2002, 18:1427–1431.
43. Bismark. [http://www.bioinformatics.babraham.ac.uk/projects/bismark/].
44. Bowtie 2. [http://bowtie-bio.sourceforge.net/bowtie2/].
45. Robinson JT, Thorvaldsdottir K, Winckler W, Guttman M, Lander ES, Getz G,
Mesirov JP: Integrative genomics viewer. Nat Biotechnol 2011, 29:24–26.
46. SAMtools. [http://samtools.sourceforge.net/].
47. ANGSD. [http://popgen.dk/wiki/index.php/ANGSD].
48. Gene Expression Omnibus (GEO). [http://www.ncbi.nlm.nih.gov/geo/].
doi:10.1186/s13059-014-0434-y
Cite this article as: Charlton et al.: Methylome analysis identifies a Wilms
tumor epigenetic biomarker detectable in blood. Genome Biology
2014 15:434.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
